Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Table 4 Characterization of the responders to combined checkpoint blockade (n = 10)

Response	Duration of response (months)	Time to response (weeks)	Treatment cycles (induction + maintenance)	Gender	Time to metastasis from primary tumor (months)	Age at treatment onset (years)	Available molecular/ genetic analysis	LDH	CRP	Risk score	Previous systemic treatment	Previous liver-directed treatment	Sites of metastasis	AE ≥ grade 3 (CTCAE v5.0)
PR	14	5	4 + 0	female	9	46	mutated: GNAQ (Q209P)	normal	normal	low	nivolumab (PD)	TACE	liver	yes (colitis)
PR	9	10	1 + 0	female	92	54	mutated: GNAQ (Q209P), ALK, MET; wildtype: BRAF, NRAS, GNA11, BAP1	normal	normal	low	none	none	lung	yes (colitis)
PR	23	10	4 + 0	female	33	77	mutated: GNA11	elevated	unknown	low	none	chemo-saturation	liver, mesenteric fat tissue	yes (Guillain-Barré syndrome)
PR	55	13	3 + 0	male	408	67	mutated: GNAQ	normal	elevated	high	none	surgery	liver, nodal	yes (colitis, hypophysitis)
PR	65	19	4 + 0	female	168	60	mutated: GNAQ; wildtype: BRAF, NRAS, KIT, GNA11	elevated	normal	high	none	TACE	liver, lung, ovarial, cervix, omentum	no
CR	53	12	4 + 5	male	unknown	59	unknown	unknown	unknown	low	none	surgery	lung	no
CR	50	12	4 + 16	male	unknown	45	unknown	elevated	elevated	very high	none	none	liver, bone, pelvic	no
PR	26	13	3 + 0	female	14	67	unknown	elevated	normal	intermediate	none	SIRT	liver, lung	yes (uveitis)
PR	25	14	4 + 1	female	30	56	wildtype: BRAF, NRAS, KIT; expression PD-L1 20%; polysomia of chromosome 12	elevated	elevated	high	none	none	liver, lung	no
PR	11	31	4 + 27	female	53	73	wildtype: BRAF, KIT, KRAS, NRAS, NF1, CDKN2A, CDK4	elevated	unknown	intermediate	none	chemo-saturation	liver, bone, nodal, renal	no

Abbreviations: CR Complete response, PR Partial response, ECOG Eastern Cooperative Oncology Group, LDH Lactate dehydrogenase, CRP C-reactive protein, TACE Transarterial chemoembolization, SIRT Selective internal radiation therapy, AE Adverse event(s), CTCAE Common Terminology Criteria for Adverse Events